What is InClin?
InClin operates as a full-service Contract Research Organization (CRO), providing essential infrastructure for pharmaceutical and biotechnology entities. Headquartered in San Mateo, California, with a significant presence in Sydney, Australia, the firm specializes in the end-to-end management of clinical trials. Their service portfolio encompasses strategic consulting, clinical operations, biometrics, and medical writing, covering the entire spectrum from Phase 1 to Phase 4 trials. By integrating deep technical expertise with agile project management, InClin enables sponsors to navigate complex regulatory environments while accelerating the delivery of innovative therapies to patients worldwide.
How much funding has InClin raised?
InClin has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in InClin
PPP
Public-Private Partnership
What's next for InClin?
With this major enterprise-level funding, InClin is positioned to scale its operational capacity and enhance its technological infrastructure. The strategic allocation of this capital will likely focus on expanding its biometrics capabilities and strengthening its global clinical trial management framework. As the demand for specialized CRO services grows, InClin is expected to leverage this investment to deepen its partnerships with drug development sponsors, ultimately driving efficiency in the clinical trial process and supporting the advancement of next-generation medical treatments.
See full InClin company page
